• Explore /
  • Poster
  • / Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).

Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Emmanuel S. Antonarakis

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Emmanuel S. Antonarakis , Josep M. Piulats , Marine Gross-Goupil , Jeffrey C. Goh , Ulka N. Vaishampayan , Ronald De Wit , Tuomo Alanko , Satoshi Fukasawa , Kenichi Tabata , Susan Feyerabend , Raanan Berger , Helen Wu , Jeri Kim , Charles Schloss , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02787005

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 104)

Abstract #

104

Poster Bd #

E6

Abstract Disclosures

Similar Posters

First Author: Emmanuel S. Antonarakis

First Author: Peter C.C. Fong

First Author: Niven Mehra

Poster

2023 ASCO Genitourinary Cancers Symposium

Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center.

Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center.

First Author: Arya Mariam Roy